Hypha Labs, Inc.

Hypha Labs, Inc. is a U.S.-based early-stage company that has shifted from cannabis/hemp testing services into developing the Hypha Micropearl bioreactor for functional mushroom cultivation. The company is currently focused on design, testing, and eventual commercialization of this device, while also seeking financing to support operations and product launch.

0.13

0.13

— Hypha Labs, Inc.
%
Bioreactor device0% The Hypha Micropearl bioreactor and related hardware intended for mushroom cultivation.
Consumables and replacement parts0% Cartridges and other recurring components used with the accelerator device.
Testing and development services0% Design, testing, validation, and technical development work for the product platform.
Legacy laboratory services100% Former cannabis and hemp testing laboratory services that were sold in 2024.

The company’s near-term customer base is expected to be limited and concentrated around early adopters of the Hypha...

  • Functional mushroom growersprimary

    Buy the bioreactor to support controlled cultivation and improve growing consistency.

  • Consumables buyersprimary

    Purchase replacement cartridges and related components for repeat use of the device.

  • Testing and validation partnerssecondary

    Provide technical feedback during product development and help validate performance.

  • Legacy cannabis/hemp testing customersemerging

    Former customers of the sold laboratory business; no longer the core revenue base.

Hypha Labs is headquartered in the United States and currently conducts limited product development and testing there...

  • •Headquartered in the United States
  • •Initial bioreactor testing is being done at company headquarters
  • •Commercial manufacturing is expected outside the United States
  • •Potential reliance on China-based suppliers/manufacturers
  • •Legacy cannabis lab operations were previously based in Nevada

The company’s strategy is to complete development and testing of the Hypha Micropearl bioreactor, then secure...

01
Finish bioreactor development and testingshort-term

Commercialization depends on proving the device works reliably before launch.

02
Secure financingshort-term

The company needs capital to fund operations, product development, and launch.

03
Establish manufacturing capacitymedium-term

Commercial sales require a scalable supply chain outside the U.S.

Hypha Labs is a going-concern-risk company with limited cash, negative working capital, and recurring losses, so...

critical

Going concern and financing shortfall

The company disclosed substantial doubt about its ability to continue without new capital.

Scope
Cash on hand, working capital, and product launch funding
Materiality
high
high

Product development and commercialization delay

The bioreactor is still in design/testing, so launch timing and market acceptance are uncertain.

Scope
Revenue timing and operating losses
Materiality
high
high

Supplier concentration and component availability

The company may rely on limited or single suppliers for cartridges and other parts.

Scope
Manufacturing continuity and product quality
Materiality
high
medium

Foreign manufacturing and trade-policy exposure

Management may use manufacturers outside the U.S., including China, creating geopolitical risk.

Scope
Cost, lead times, and supply continuity
Materiality
medium
medium

Customer concentration in an early-stage launch

Initial sales may depend on a small number of customers and repeat cartridge purchases.

Scope
Revenue volatility and order timing
Materiality
medium
Going concern
May require heightened scrutiny of asset recoverability and financing assumptions
Stock-based compensation
Can materially affect operating expenses and net loss
Fair value measurements
Affects reported values for cash equivalents and any measured liabilities
Expense volatility
Quarterly results may not be directly comparable

KYNTRA BIO, INC.

KYNB · Pharmaceutical Preparations

Kymera Therapeutics, Inc.

KYMR · Biological Products, (No Diagnostic Substances)

Bicara Therapeutics Inc.

BCAX · Pharmaceutical Preparations

MUSTANG BIO, INC.

MBIO · Pharmaceutical Preparations

Papa Medical Inc.

Cigarettes

HOOKIPA Pharma Inc.

HOOK · Pharmaceutical Preparations

: 28/04/2026